Pressemitteilungen

externe Meldungen

01.09.2022

Medigene AG

MEDIGENE PARTICIPATES AT UPCOMING SCIENTIFIC CONFERENCES

Planegg/Martinsried - Medigene AG ( http://www.medigene.com) (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology company focusing on the development of T-cell-based cancer therapies, will participate at the following upcoming scientific conferences. Medigene's management and/or scientists will be available for one-on-one meetings at these events.

7th CAR-TCR Summit
19-22 Sepx"box-sizing: border-box;">Boston, MA, USA
https://car-tcr-summit.com/

Immuno UK
29-30 Sepx"box-sizing: border-box;">London, United Kingdom
https://www.oxfordglobal.co.uk/immuno-series-uk/

10th Annual Immuno-Oncology Summit
12-14 October 2022
Boston, MA, USA
https://www.immuno-oncologysummit.com/

Cell UK
7-8 November 2022
London, United Kingdom
https://www.oxfordglobal.co.uk/cell-series-uk/

--- end of press release ---

About Medigene

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Planegg/Martinsried near Munich, Germany. With its scientific expertise, Medigene is working on the development of innovative immunotherapies to enhance T cell activity against solid cancers in fields of high unmet medical need.

Medigene's strategy is to both develop its own therapies as well as to offer selected partners the opportunity to discover and develop therapies on the basis of its proprietary technology platforms. In return for such partnerships, Medigene expects to receive upfront and milestone payments as well as research and development funding and royalties on future product sales.

For more information, please visit https://www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Medigene

Dr. Anna Niedl
Phone: +49 89 2000 3333 01
E-mail: investor@medigene.com

LifeSci Advisors

Sandya von der Weid
Phone: +41 78 680 05 38
E-mail: svonderweid@lifesciadvisors.com


Newsletter

Anmeldung

Archiv